- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | NeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83 | 2 | Seeking Alpha | ||
| Fr | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.09. | XFRA H1Z: WIEDERAUFNAHME/RESUMPTION | 196 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.09. | XFRA H1Z: AUSSETZUNG/SUSPENSION | 281 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEUROSENSE THERAPEUTICS... ► Artikel lesen | |
| 14.09. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.09.2026 | 255 | Xetra Newsboard | Das Instrument USZ0 AU0000284366 BPH GLOBAL LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 14.09.2026 und ex Kapitalmassnahme am 15.09.2026 The instrument USZ0 AU0000284366 BPH GLOBAL LTD. EQUITY... ► Artikel lesen | |
| 09.09. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.08. | NeuroSense Issues CEO Letter to Shareholders | 340 | PR Newswire | CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused... ► Artikel lesen | |
| 06.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 29.06. | NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | 233 | PR Newswire | First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
TDP-43 pathology is... ► Artikel lesen | |
| 25.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | 325 | PR Newswire | PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with... ► Artikel lesen | |
| 18.06. | Halberd Corp.: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring | 3 | GlobeNewswire (USA) | ||
| 08.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.04. | NeuroSense Therapeutics receives Nasdaq notices over listing requirements | 20 | Seeking Alpha | ||
| 03.04. | NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | 328 | PR Newswire | Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics reports FY results, GAAP EPS of $0.44 | 2 | Seeking Alpha | ||
| 31.03. | NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | 601 | PR Newswire | 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
Statistically significant survival benefit demonstrated... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 1,490 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx's Efficacy | Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance.
The MAVERIC Steering Committee recommends expanding enrollment... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,800 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,240 | -5,70 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| CEL-SCI | 1,390 | 0,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,603 | +0,17 % | Moleculin Biotech, Inc.: Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 | Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept.... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 0,732 | +4,27 % | PDS Biotech reports 39.3-month survival data for HPV16 therapy | ||
| LISATA THERAPEUTICS | 1,230 | 0,00 % | Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it? | ||
| GEOVAX LABS | 0,355 | +1,03 % | EQS-News: GeoVax, Inc.: GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models 21.09.2026 / 14:37 CET/CEST
The... ► Artikel lesen | |
| COCRYSTAL | 0,980 | -2,97 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| DECOY THERAPEUTICS | 3,080 | -0,32 % | Decoy Therapeutics, Inc: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding | Next-Generation D-MAVs Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility
... ► Artikel lesen | |
| JASPER THERAPEUTICS | 0,609 | 0,00 % | NSE - Jasper Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CHEMOMAB THERAPEUTICS | 2,180 | +0,93 % | Chemomab Therapeutics Ltd. - S-4, Registration of securities, business combinations | ||
| VISTAGEN THERAPEUTICS | 0,273 | 0,00 % | Vistagen Therapeutics, Inc.: Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder | Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on "Publications" section of Company's website SOUTH SAN FRANCISCO, Calif., Sept.... ► Artikel lesen | |
| IN8BIO | 0,990 | -7,48 % | IN8bio auf der Sidoti Small Cap Virtual Conference: Offensive mit Gamma-Delta-T-Zellen | ||
| METAVIA | 1,660 | 0,00 % | MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support... ► Artikel lesen |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.